Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. Mar S, Valeriani M, Steinborn B, Schreiner T, et al. J Neurol 2025;272:137.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mar S, Valeriani M, Steinborn B, Schreiner T, et al. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol 2025;272:137.
PMID: 39812825